153.20
153.20 (0%)
As of Feb 14, 2025
GLAUKOS Corp [GKOS]
Source:
Company Overview
Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal disease.
| Country | United States |
| Headquarters | aliso viejo, california |
| Phone Number | 949-367-9600 |
| Industry | manufacturing |
| CEO | Thomas W. Burns |
| Website | www.glaukos.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $383.5 |
| Operating Profit | $-122.4 |
| Net Income | $-146.4 |
| Net Cash | $75 |
Profit Ratios
| Gross Margin | $289.5 |
| Operating Margin | -31.9 |
| Profit as % of Revenues | -197.8% |
| Profit as % of Assets | -15.3% |
| Profit as % of Stockholder Equity | -19.1% |
Management Effectiveness
| Return on Equity | -19.1% |
| Return on Assets | -15% |
| Turnover Ratio | 40.1% |
| EBITA | $-122.4 |
Balance Sheet and Cash Flow Measures
| Total Assets | $974.8 |
| Total Liabilities | $207.8 |
| Operating Cash Flow | $-61.3 |
| Investing Cash Flow | $47.8 |
| Financing Cash Flow | $91.5 |
